Gain Therapeutics (GANX) Short Interest Ratio & Short Volume → get a piece of the profit from this land (From True Market Insiders) (Ad) Free GANX Stock Alerts $2.63 -0.06 (-2.23%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Gain Therapeutics Short Interest DataCurrent Short Volume154,200 sharesPrevious Short Volume149,600 sharesChange Vs. Previous Month+3.07%Dollar Volume Sold Short$451,806.00Short Interest Ratio / Days to Cover1.0Last Record DateApril 30, 2024Outstanding Shares18,050,000 sharesFloat Size15,090,000 sharesShort Percent of Float1.02%Today's Trading Volume59,339 sharesAverage Trading Volume121,464 sharesToday's Volume Vs. Average49% Short Selling Gain Therapeutics ? Sign up to receive the latest short interest report for Gain Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatGANX Short Interest Over TimeGANX Days to Cover Over TimeGANX Percentage of Float Shorted Over Time Ad InvestorPlaceMillionaire Investor makes surprising election predictionMillionaire Investor Makes Surprising Election Prediction Louis Navellier says he knows who's going to win the election. And how they could send six specific AI stocks through the roof on their first day.Click here for the full story… Gain Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2024154,200 shares $451,806.00 +3.1%1.0%1 $2.93 4/15/2024149,600 shares $462,264.00 +8.3%1.1%0.9 $3.09 3/31/2024138,100 shares $520,637.00 -11.9%1.0%0.9 $3.77 3/15/2024156,700 shares $672,243.00 +16.4%0.9%0.9 $4.29 2/29/2024134,600 shares $604,354.00 -2.2%0.8%0.8 $4.49 2/15/2024137,600 shares $660,480.00 +13.4%0.8%0.9 $4.80 Get the Latest News and Ratings for GANX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024121,300 shares $469,431.00 +17.2%0.7%0.8 $3.87 1/15/2024103,500 shares $361,215.00 +66.1%0.6%1.2 $3.49 12/31/202362,300 shares $203,409.50 -42.0%0.4%0.7 $3.27 12/15/2023107,400 shares $268,500.00 -25.0%0.6%1.6 $2.50 11/30/2023143,200 shares $306,448.00 -18.9%1.2%2.4 $2.14 11/15/2023176,500 shares $511,850.00 -3.2%1.7%3.8 $2.90 10/31/2023182,400 shares $521,664.00 -9.5%1.8%4.9 $2.86 10/15/2023201,600 shares $665,280.00 +6.4%2.0%4.8 $3.30 9/30/2023189,500 shares $621,560.00 +5.2%1.9%4.5 $3.28 9/15/2023180,100 shares $666,370.00 +14.1%1.8%5.5 $3.70 8/31/2023157,900 shares $522,649.00 -6.4%1.6%4.5 $3.31 8/15/2023168,600 shares $606,960.00 +61.5%1.7%4.3 $3.60 7/31/2023104,400 shares $414,468.00 +66.0%1.1%2.3 $3.97 7/15/202362,900 shares $279,276.00 -6.5%0.7%0.9 $4.44 6/30/202367,300 shares $301,504.00 +21.7%0.7%1 $4.48 6/15/202355,300 shares $269,311.00 +24.8%0.6%0.8 $4.87 5/31/202344,300 shares $204,223.00 -19.6%0.5%0.5 $4.61 5/15/202355,100 shares $279,908.00 -7.9%0.6%0.7 $5.08 4/30/202359,800 shares $300,794.00 -7.1%0.7%0.8 $5.03 4/15/202364,400 shares $308,476.00 +7.3%0.7%0.9 $4.79 3/31/202360,000 shares $289,200.00 +20.2%0.7%1.1 $4.82 3/15/202349,900 shares $220,558.00 +64.1%0.6%0.9 $4.42 2/28/202330,400 shares $126,464.00 +35.7%0.3%0.7 $4.16 2/15/202322,400 shares $87,360.00 -16.7%0.3%0.5 $3.90 1/31/202326,900 shares $106,255.00 +45.4%0.3%0.7 $3.95 1/15/202318,500 shares $71,783.70 -70.5%0.2%0.5 $3.88 12/30/202262,700 shares $196,251.00 -10.7%0.6%1.9 $3.13 12/15/202270,200 shares $210,600.00 +146.3%0.7%2.3 $3.00 11/30/202228,500 shares $86,640.00 -25.4%0.3%1 $3.04 11/15/202238,200 shares $119,184.00 -21.1%0.4%1.2 $3.12 10/31/202248,400 shares $161,656.00 +6.6%0.5%1.4 $3.34 10/15/202245,400 shares $143,010.00 -30.3%0.5%1.2 $3.15 9/30/202265,100 shares $212,226.00 +50.0%0.8%1.5 $3.26 9/15/202243,400 shares $169,260.00 +80.8%0.6%1 $3.90[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. GANX Short Interest - Frequently Asked Questions What is Gain Therapeutics' current short interest? Short interest is the volume of Gain Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 154,200 shares of GANX short. 1.02% of Gain Therapeutics' shares are currently sold short. Learn More on Gain Therapeutics' current short interest. What is a good short interest ratio for Gain Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GANX shares currently have a short interest ratio of 1.0. Learn More on Gain Therapeutics's short interest ratio. What is a good short interest percentage for Gain Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.02% of Gain Therapeutics' floating shares are currently sold short. Is Gain Therapeutics' short interest increasing or decreasing? Gain Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 154,200 shares, an increase of 3.1% from the previous total of 149,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Gain Therapeutics' float size? Gain Therapeutics currently has issued a total of 18,050,000 shares. Some of Gain Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Gain Therapeutics currently has a public float of 15,090,000 shares. How does Gain Therapeutics' short interest compare to its competitors? 1.02% of Gain Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Gain Therapeutics: Eyenovia, Inc. (11.45%), CASI Pharmaceuticals, Inc. (0.73%), VYNE Therapeutics Inc. (0.68%), Unicycive Therapeutics, Inc. (2.13%), HCW Biologics Inc. (0.05%), Ocuphire Pharma, Inc. (4.71%), Xilio Therapeutics, Inc. (5.24%), NextCure, Inc. (0.53%), Lexaria Bioscience Corp. (2.29%), Cara Therapeutics, Inc. (5.62%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Gain Therapeutics stock? Short selling GANX is an investing strategy that aims to generate trading profit from Gain Therapeutics as its price is falling. GANX shares are trading down $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Gain Therapeutics? A short squeeze for Gain Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GANX, which in turn drives the price of the stock up even further. How often is Gain Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GANX, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: EYEN Short Squeeze CASI Short Squeeze VYNE Short Squeeze UNCY Short Squeeze HCWB Short Squeeze OCUP Short Squeeze XLO Short Squeeze NXTC Short Squeeze LEXX Short Squeeze CARA Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GANX) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceWhat’s Really Next for America…Porter & Company[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyMissed NVDA? Buy this AI stock NOWChaikin Analytics